If you have been following the latest news about medical weight loss, GLP-1 medications, or the newest obesity treatments, you may have heard a new name: retatrutide.
Some people are already calling retatrutide the “next generation” of weight loss medication because it targets three different hormone receptors involved in appetite, blood sugar, and metabolism.
But what exactly is retatrutide? How is it different from semaglutide and tirzepatide? And does targeting three hormone pathways really make a difference?
At Sage Wellness and Medspa in Plantation, Florida, we believe patients deserve clear, medically grounded information about weight loss medications—not social media hype or unrealistic promises.
Here is what you need to know about retatrutide and the future of medically supervised weight loss.
What Is Retatrutide?
Retatrutide is an investigational once-weekly injectable medication currently being studied for obesity, overweight, type 2 diabetes, and several obesity-related health conditions.
It is often referred to as a triple hormone receptor agonist or “triple agonist.”
Why?
Because retatrutide activates three hormone receptor pathways:
GLP-1: glucagon-like peptide-1
GIP: glucose-dependent insulinotropic polypeptide
Glucagon
This is what makes retatrutide different from current medications such as semaglutide and tirzepatide.
Semaglutide targets one primary hormone receptor pathway.
Tirzepatide targets two hormone receptor pathways.
Retatrutide targets three.
It is important to understand that retatrutide is still investigational and is not currently FDA-approved for weight loss or any other indication. Patients should be extremely cautious about websites or companies claiming to sell retatrutide online.
The FDA has specifically warned consumers about unapproved GLP-1 products and products falsely labeled “for research purposes” or “not for human consumption.” These products may be of unknown quality and may pose health risks.
How Does Retatrutide Work?
To understand why researchers are so interested in retatrutide, it helps to understand the three hormone pathways it targets.
1. GLP-1 Helps Control Hunger and Appetite
GLP-1 is a naturally occurring hormone involved in appetite regulation, food intake, and glucose control.
Activating GLP-1 receptors may help:
Reduce hunger
Increase feelings of fullness
Reduce caloric intake
Improve glucose regulation
Decrease “food noise” for some patients
GLP-1 receptor activation is the primary mechanism used by semaglutide.
For many patients, this can make following a healthy nutrition plan significantly more manageable.
Instead of feeling like they are constantly fighting hunger, patients may feel satisfied with smaller portions and experience fewer persistent thoughts about food.
2. GIP Adds a Second Metabolic Pathway
GIP is another hormone involved in the body’s response to food and glucose.
Tirzepatide activates both GIP and GLP-1 receptors.
This dual mechanism is one of the major differences between tirzepatide and semaglutide.
In the SURMOUNT-5 head-to-head clinical trial involving adults with obesity without diabetes, participants treated with tirzepatide experienced an average body weight reduction of approximately 20.2% at 72 weeks compared with 13.7% with semaglutide.
This does not mean tirzepatide is automatically the best medication for every patient. Medication selection should consider medical history, side effects, contraindications, access, and the individual patient’s response to treatment.
It does, however, demonstrate why scientists continue to study medications that target multiple metabolic pathways.
3. Glucagon May Affect Energy Metabolism
This is where retatrutide becomes particularly interesting.
Retatrutide adds glucagon receptor activity to GLP-1 and GIP receptor activity.
Most people associate glucagon primarily with blood sugar regulation. However, glucagon signaling is also being studied for its potential effects on energy expenditure and metabolic function.
Think of it this way:
Semaglutide may help turn down hunger.
Tirzepatide may turn down hunger while activating two complementary metabolic hormone pathways.
Retatrutide is being studied to determine whether targeting appetite, glucose-related pathways, and energy metabolism together may produce even greater metabolic and weight loss effects.
Researchers are sometimes informally describing this approach as a potential “triple G” strategy because retatrutide targets GLP-1, GIP, and glucagon receptors.
How Much Weight Have Patients Lost With Retatrutide in Clinical Trials?
The clinical trial results surrounding retatrutide have received significant attention.
In a Phase 2 clinical trial published in The New England Journal of Medicine, once-weekly retatrutide produced substantial, dose-dependent weight reduction. At 48 weeks, participants receiving the 12 mg dose had an average weight reduction of approximately 24.2%.
More recently, Eli Lilly reported Phase 3 TRIUMPH-1 results showing that participants receiving 12 mg of retatrutide lost an average of approximately 28.3% of their body weight over 80 weeks. In that trial, 45.3% of participants at the 12 mg dose achieved at least 30% body weight reduction.
These are extraordinary research findings.
However, there is an important distinction patients need to understand:
Clinical trial results are averages—not promises.
Individual weight loss can vary significantly based on:
Starting weight
Metabolic health
Insulin resistance
Medical conditions
Medication tolerance
Nutrition
Protein intake
Physical activity
Muscle mass
Sleep
Stress
Medication adherence
Behavioral patterns
This is exactly why we do not believe successful medical weight loss should ever be reduced to simply mailing someone medication and saying, “See you next month.”
Retatrutide vs. Tirzepatide vs. Semaglutide: What Is the Difference?
Here is a simple comparison:
| Medication | Hormone Receptors Targeted | Primary Mechanism | Current Status |
|---|---|---|---|
| Semaglutide | GLP-1 | Appetite and caloric intake regulation | FDA-approved products are available for specific diabetes and weight management indications |
| Tirzepatide | GIP + GLP-1 | Dual incretin receptor activity affecting appetite, food intake, and glucose regulation | FDA-approved products are available for specific diabetes and chronic weight management indications |
| Retatrutide | GIP + GLP-1 + Glucagon | Triple hormone receptor activity being studied for appetite and metabolic effects | Investigational and not currently FDA-approved |
Semaglutide: The Single Agonist
Semaglutide is a GLP-1 receptor agonist.
It has changed the medical weight loss industry by demonstrating that obesity can be treated as a chronic metabolic disease rather than simply telling patients to “eat less and exercise more.”
Semaglutide may help reduce appetite and caloric intake and improve glucose-related metabolic function.
For the right patient, it can be an extremely valuable weight management tool.
Tirzepatide: The Dual Agonist
Tirzepatide activates both GIP and GLP-1 receptors.
This dual mechanism has demonstrated significant weight reduction in clinical trials.
In a direct clinical comparison published in The New England Journal of Medicine, tirzepatide resulted in greater average weight reduction than semaglutide in adults with obesity without diabetes.
Again, this does not mean one medication is appropriate for every patient.
At Sage Wellness, we look at the individual person—not just the medication name trending on social media.
Retatrutide: The Investigational Triple Agonist
Retatrutide activates:
GIP + GLP-1 + glucagon receptors.
The addition of glucagon receptor activity is one of the primary reasons researchers are so interested in this medication.
Early and Phase 3 clinical trial results reported to date have demonstrated substantial weight reduction.
However, retatrutide has not been directly proven superior to tirzepatide in a completed head-to-head clinical trial. A direct comparison study is important because comparing percentages from separate clinical trials can be misleading.
Retatrutide also remains investigational.
At Sage Wellness, we believe in being excited about advances in obesity medicine while remaining honest about where the science currently stands.
What Are the Potential Benefits of Retatrutide?
Based on clinical research to date, potential areas of benefit being studied include:
Significant body weight reduction. Retatrutide has demonstrated substantial average weight reduction in clinical trials.
Reduced appetite and food intake. GLP-1 receptor activation plays an important role in appetite and caloric intake regulation.
Improved glucose control. Retatrutide is also being studied in patients with type 2 diabetes, and Phase 3 data reported by Lilly have demonstrated reductions in A1C and body weight.
Potential effects on metabolic health. Researchers are evaluating retatrutide across multiple obesity-related and metabolic conditions.
Potential improvements in obesity-related conditions. Clinical trials are studying retatrutide in patients with cardiovascular disease, obstructive sleep apnea, knee osteoarthritis, chronic low back pain, and metabolic liver disease.
These potential benefits remain areas of active scientific research. Retatrutide should not be considered FDA-approved to prevent or treat these conditions at this time.
Is Retatrutide FDA Approved?
No.
As of July 2026, retatrutide is an investigational medication and is not FDA-approved.
Eli Lilly is studying retatrutide in an extensive Phase 3 clinical trial program.
This is particularly important because patients may see advertisements online claiming to sell “retatrutide peptides” or “research retatrutide.”
The FDA has warned about unapproved drugs containing or claiming to contain retatrutide that are marketed directly to consumers.
Patients should never assume that a vial purchased online contains the correct ingredient, concentration, sterility, or quality simply because the label says “retatrutide.”
What Are the Side Effects of Retatrutide?
In clinical trials, gastrointestinal side effects have been among the most commonly reported adverse events.
These may include:
Nausea
Diarrhea
Vomiting
Constipation
Decreased appetite
Clinical research has also evaluated changes in heart rate and other safety measures.
Because retatrutide remains investigational, its complete long-term safety profile is still being established.
This is another reason medical supervision matters.
Weight loss medication should not simply be about finding the strongest medication available.
The goal should be finding the safest, most appropriate, and most sustainable treatment strategy for the individual patient.
Why Weight Loss Medication Alone Is Not the Entire Answer
This is where we do things differently at Sage Wellness and Medspa.
A medication may help decrease hunger.
It cannot automatically teach you how much protein your body needs.
It cannot recognize that you are losing muscle instead of fat.
It cannot call you out when every weekend is undoing the progress you made Monday through Thursday.
It cannot help you understand why your weight loss has suddenly stalled.
It cannot look at your eating habits and identify that you are consuming too few calories—or too many hidden calories.
And it cannot provide accountability.
That is where individualized medical weight loss support becomes so important.
At Sage Wellness, we have extensive experience helping patients navigate medically supervised weight loss.
Our approach is centered around one-on-one support, weight loss coaching, accountability, education, and individualized care.
We want to know what is actually happening between your appointments.
Are you getting enough protein?
Are you drinking enough water?
Are you constipated?
Are you losing muscle?
Has your appetite changed?
Are your weekends becoming difficult?
Are you experiencing side effects?
Has your weight stalled?
Do we need to reassess your plan?
These are the conversations that can make the difference between simply taking a weight loss medication and actually learning how to create sustainable change.
The Sage Wellness Difference: You Are More Than a Number on the Scale
One of our biggest concerns with the rapid growth of online weight loss programs is that many patients feel like they are simply being shipped medication.
At Sage Wellness, our philosophy is different.
We believe successful weight loss requires a relationship between the patient and the healthcare provider.
Our medically supervised weight loss program focuses on:
One-on-one weight loss support
Individualized medical evaluation
Weight loss coaching
Regular accountability
Nutrition education
Protein intake guidance
Body composition awareness
Side effect management
Plateau troubleshooting
Sustainable lifestyle changes
We do not expect perfection.
We expect honesty, communication, and a willingness to work together.
Because the truth is that even the most advanced weight loss medication cannot replace personalized care.
Is Semaglutide or Tirzepatide Right for You?
The answer depends on you.
Your medical history matters.
Your previous weight loss attempts matter.
Your current medications matter.
Your appetite patterns matter.
Your metabolic health matters.
Your goals matter.
And your ability to tolerate a medication matters.
There is no single “best” weight loss medication for every person.
During your weight loss consultation at Sage Wellness and Medspa, we can discuss your history, your weight loss goals, and the medically appropriate treatment options currently available to you.
Ready to Start Your Weight Loss Journey in Plantation, Florida?
You do not need to wait for the “next big weight loss drug” to begin working on your health.
And you do not need to navigate medical weight loss alone.
At Sage Wellness and Medspa in Plantation, Florida, our goal is to provide the personalized support, medical guidance, coaching, and accountability that can help you build a more successful weight loss journey.
Whether you are researching semaglutide, tirzepatide, GLP-1 weight loss medications, or simply want to understand why your previous weight loss attempts have not worked, we are here to help you create an individualized plan.
Ready to find out which weight loss approach may be right for you?
Book your medical weight loss appointment with Sage Wellness and Medspa in Plantation, Florida today.
Come meet with a provider who will listen to your story, understand your goals, and help you develop a personalized weight loss strategy.
Book your consultation today and discover the Sage Wellness difference: personalized care, real accountability, and one-on-one support throughout your weight loss journey.
Medical Disclaimer: This article is for educational purposes only and does not constitute individual medical advice. Retatrutide is investigational and is not currently FDA-approved. Weight loss medications are not appropriate for every patient. A medical evaluation is necessary to determine whether a prescription weight management treatment is appropriate for you.
